| The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma J Bauer, N Köhler, Y Maringer, P Bucher, T Bilich, M Zwick, S Dicks, ... Nature Communications 13 (1), 6401, 2022 | 19 | 2022 |
| Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency JS Heitmann, C Tandler, M Marconato, A Nelde, T Habibzada, SM Rittig, ... Nature Communications 14 (1), 5032, 2023 | 8 | 2023 |
| DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts A Goyal, J Bauer, J Hey, DN Papageorgiou, E Stepanova, M Daskalakis, ... Nature communications 14 (1), 6731, 2023 | 6 | 2023 |
| HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients CM Tegeler, J Scheid, HG Rammensee, HR Salih, JS Walz, JS Heitmann, ... Cancers 14 (9), 2260, 2022 | 6 | 2022 |
| TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification N Hoenisch Gravel, A Nelde, J Bauer, L Mühlenbruch, SM Schroeder, ... Nature Communications 14 (1), 7472, 2023 | 4 | 2023 |
